# A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)

> **NCT03020797** · NA · TERMINATED · sponsor: **Stony Brook University** · enrollment: 12 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Perampanel
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03020797
- **Lead sponsor:** Stony Brook University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01-12
- **Primary completion:** 2023-01-31
- **Final completion:** 2023-02-08
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** 1\) Enrolment below study target and 2) too many subjects had early termination due to disease progression.
- **Last updated:** 2023-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03020797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03020797, "A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03020797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*